Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Clinical trial NCT02752828 · COMPLETED
Trial details
- NCT number
- NCT02752828
- Sponsor
- Sanofi
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-23
- Primary completion
- 2018-03-12
- Enrollment
- 521
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.